Julia Lenore Marcus, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 79 | 2024 | 16678 | 5.770 |
Why?
|
Anti-HIV Agents | 38 | 2024 | 4250 | 5.640 |
Why?
|
Homosexuality, Male | 36 | 2024 | 1238 | 3.620 |
Why?
|
Hepatitis C | 8 | 2021 | 1582 | 2.180 |
Why?
|
Acquired Immunodeficiency Syndrome | 7 | 2023 | 2231 | 1.900 |
Why?
|
Sexually Transmitted Diseases | 9 | 2021 | 622 | 1.790 |
Why?
|
Gonorrhea | 10 | 2020 | 335 | 1.540 |
Why?
|
Chlamydia Infections | 10 | 2020 | 364 | 1.510 |
Why?
|
Antiviral Agents | 7 | 2021 | 2978 | 1.390 |
Why?
|
Sexual Behavior | 15 | 2023 | 2050 | 1.370 |
Why?
|
HIV | 9 | 2023 | 1600 | 1.360 |
Why?
|
Hepacivirus | 8 | 2021 | 1372 | 1.340 |
Why?
|
Adenine | 5 | 2020 | 936 | 1.340 |
Why?
|
Safe Sex | 2 | 2019 | 141 | 1.170 |
Why?
|
Fluorenes | 2 | 2018 | 159 | 1.170 |
Why?
|
California | 12 | 2021 | 1400 | 1.060 |
Why?
|
Prescription Drugs | 2 | 2022 | 595 | 1.030 |
Why?
|
Anti-Retroviral Agents | 4 | 2024 | 1712 | 1.030 |
Why?
|
Delivery of Health Care, Integrated | 5 | 2022 | 941 | 1.010 |
Why?
|
Sexual Partners | 9 | 2023 | 730 | 1.000 |
Why?
|
Sexually Transmitted Diseases, Bacterial | 2 | 2021 | 24 | 0.950 |
Why?
|
Hepatitis C, Chronic | 3 | 2021 | 1027 | 0.920 |
Why?
|
Neisseria gonorrhoeae | 5 | 2017 | 238 | 0.900 |
Why?
|
Contact Tracing | 5 | 2021 | 272 | 0.890 |
Why?
|
Rectal Diseases | 4 | 2019 | 142 | 0.890 |
Why?
|
Benzimidazoles | 2 | 2018 | 848 | 0.880 |
Why?
|
Nonprescription Drugs | 1 | 2023 | 116 | 0.850 |
Why?
|
Syphilis | 4 | 2019 | 226 | 0.840 |
Why?
|
Life Expectancy | 2 | 2020 | 1183 | 0.810 |
Why?
|
Unsafe Sex | 2 | 2021 | 220 | 0.800 |
Why?
|
Deoxycytidine | 3 | 2014 | 824 | 0.780 |
Why?
|
San Francisco | 13 | 2020 | 159 | 0.750 |
Why?
|
Condoms | 2 | 2021 | 323 | 0.740 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 28 | 0.720 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 32 | 0.720 |
Why?
|
Epidemics | 2 | 2021 | 521 | 0.630 |
Why?
|
CD4 Lymphocyte Count | 5 | 2018 | 2557 | 0.630 |
Why?
|
Insurance, Health | 3 | 2020 | 2493 | 0.620 |
Why?
|
Drug Costs | 2 | 2022 | 1104 | 0.610 |
Why?
|
Chlamydia | 2 | 2018 | 33 | 0.570 |
Why?
|
Health Communication | 1 | 2020 | 213 | 0.570 |
Why?
|
Holistic Health | 1 | 2016 | 47 | 0.560 |
Why?
|
Common Variable Immunodeficiency | 1 | 2017 | 93 | 0.560 |
Why?
|
Health Services Accessibility | 4 | 2023 | 5133 | 0.550 |
Why?
|
Humans | 110 | 2024 | 742088 | 0.540 |
Why?
|
Dideoxynucleosides | 1 | 2016 | 122 | 0.540 |
Why?
|
Chemoprevention | 2 | 2015 | 319 | 0.510 |
Why?
|
Medication Adherence | 6 | 2021 | 2055 | 0.500 |
Why?
|
Primary Health Care | 6 | 2021 | 4551 | 0.500 |
Why?
|
Male | 67 | 2024 | 349538 | 0.500 |
Why?
|
Viral Load | 3 | 2021 | 3292 | 0.490 |
Why?
|
Incidence | 16 | 2024 | 20928 | 0.470 |
Why?
|
Urethra | 3 | 2013 | 408 | 0.440 |
Why?
|
Pneumococcal Vaccines | 1 | 2016 | 390 | 0.440 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 820 | 0.440 |
Why?
|
Herpesvirus 2, Human | 1 | 2014 | 185 | 0.430 |
Why?
|
Chlamydia trachomatis | 4 | 2017 | 245 | 0.420 |
Why?
|
Sentinel Surveillance | 3 | 2013 | 281 | 0.420 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1636 | 0.410 |
Why?
|
Oropharynx | 2 | 2017 | 127 | 0.410 |
Why?
|
Pneumococcal Infections | 1 | 2016 | 496 | 0.410 |
Why?
|
Urethritis | 1 | 2011 | 22 | 0.400 |
Why?
|
Adult | 46 | 2023 | 213712 | 0.400 |
Why?
|
Syphilis Serodiagnosis | 1 | 2011 | 35 | 0.390 |
Why?
|
Ambulatory Care Facilities | 6 | 2018 | 932 | 0.390 |
Why?
|
Herpes Simplex | 1 | 2014 | 466 | 0.380 |
Why?
|
Language | 1 | 2020 | 1458 | 0.370 |
Why?
|
Proctitis | 1 | 2010 | 40 | 0.360 |
Why?
|
Middle Aged | 36 | 2023 | 213127 | 0.350 |
Why?
|
Mass Screening | 6 | 2020 | 5238 | 0.340 |
Why?
|
Communicable Diseases, Emerging | 1 | 2011 | 156 | 0.340 |
Why?
|
Pharynx | 1 | 2011 | 413 | 0.330 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2021 | 3915 | 0.330 |
Why?
|
Risk Reduction Behavior | 4 | 2020 | 1123 | 0.310 |
Why?
|
Female | 42 | 2023 | 379592 | 0.310 |
Why?
|
Alanine | 2 | 2020 | 572 | 0.310 |
Why?
|
Communication | 2 | 2021 | 3728 | 0.310 |
Why?
|
Patient-Centered Care | 2 | 2021 | 1436 | 0.290 |
Why?
|
Health Promotion | 2 | 2016 | 2194 | 0.290 |
Why?
|
Rectum | 1 | 2011 | 903 | 0.280 |
Why?
|
United States | 17 | 2023 | 69693 | 0.280 |
Why?
|
Costs and Cost Analysis | 2 | 2022 | 1679 | 0.280 |
Why?
|
Primary Prevention | 1 | 2014 | 1166 | 0.280 |
Why?
|
Cohort Studies | 13 | 2023 | 40450 | 0.280 |
Why?
|
Pneumonia | 1 | 2017 | 2117 | 0.260 |
Why?
|
Patient Compliance | 2 | 2017 | 2680 | 0.250 |
Why?
|
Risk-Taking | 3 | 2021 | 986 | 0.250 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2337 | 0.250 |
Why?
|
Prevalence | 11 | 2020 | 15194 | 0.250 |
Why?
|
Prostate-Specific Antigen | 1 | 2014 | 2458 | 0.250 |
Why?
|
Patient Acceptance of Health Care | 4 | 2022 | 3014 | 0.220 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3151 | 0.220 |
Why?
|
Young Adult | 17 | 2021 | 56350 | 0.220 |
Why?
|
Motivation | 2 | 2022 | 1968 | 0.210 |
Why?
|
Orgasm | 1 | 2021 | 64 | 0.200 |
Why?
|
Neoplasms | 3 | 2021 | 21596 | 0.200 |
Why?
|
Georgia | 1 | 2021 | 185 | 0.190 |
Why?
|
Interviews as Topic | 4 | 2019 | 2536 | 0.190 |
Why?
|
Africa, Eastern | 1 | 2020 | 71 | 0.190 |
Why?
|
Child Abuse | 1 | 2009 | 1030 | 0.180 |
Why?
|
Levonorgestrel | 1 | 2020 | 77 | 0.180 |
Why?
|
Glycolipids | 1 | 2000 | 205 | 0.170 |
Why?
|
Aged | 15 | 2021 | 162944 | 0.170 |
Why?
|
Hepatitis C Antibodies | 1 | 2019 | 145 | 0.170 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2019 | 52 | 0.170 |
Why?
|
Awards and Prizes | 1 | 2023 | 375 | 0.170 |
Why?
|
Hospitalization | 1 | 2018 | 10232 | 0.160 |
Why?
|
Kenya | 1 | 2020 | 685 | 0.160 |
Why?
|
Risk | 3 | 2021 | 9679 | 0.160 |
Why?
|
Intention | 1 | 2020 | 338 | 0.150 |
Why?
|
Electronic Health Records | 4 | 2024 | 4440 | 0.150 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2016 | 1872 | 0.150 |
Why?
|
Treatment Outcome | 6 | 2020 | 62966 | 0.150 |
Why?
|
Models, Statistical | 2 | 2023 | 5100 | 0.150 |
Why?
|
Risk Factors | 11 | 2021 | 72145 | 0.140 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 468 | 0.140 |
Why?
|
Oligodendroglia | 1 | 2000 | 514 | 0.140 |
Why?
|
Myelin Sheath | 1 | 2000 | 652 | 0.140 |
Why?
|
Uganda | 1 | 2020 | 1239 | 0.140 |
Why?
|
Managed Care Programs | 1 | 2021 | 949 | 0.130 |
Why?
|
Malnutrition | 1 | 2022 | 625 | 0.130 |
Why?
|
Viremia | 1 | 2019 | 735 | 0.130 |
Why?
|
Cannabis | 1 | 2021 | 432 | 0.130 |
Why?
|
Adolescent | 9 | 2021 | 85649 | 0.130 |
Why?
|
Health Personnel | 4 | 2023 | 3210 | 0.130 |
Why?
|
Vaccines, Conjugate | 1 | 2016 | 331 | 0.130 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 783 | 0.130 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 7770 | 0.120 |
Why?
|
Recurrence | 3 | 2018 | 8333 | 0.120 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 546 | 0.120 |
Why?
|
Needle Sharing | 1 | 2013 | 24 | 0.120 |
Why?
|
Genotype | 2 | 2018 | 12946 | 0.110 |
Why?
|
Models, Biological | 1 | 2010 | 9581 | 0.110 |
Why?
|
Health Maintenance Organizations | 1 | 2016 | 642 | 0.110 |
Why?
|
Sex Distribution | 1 | 2018 | 2295 | 0.110 |
Why?
|
Pandemics | 3 | 2022 | 8328 | 0.110 |
Why?
|
Retrospective Studies | 9 | 2023 | 77098 | 0.110 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13019 | 0.110 |
Why?
|
Tobacco Use Disorder | 1 | 2018 | 685 | 0.110 |
Why?
|
Malaria | 1 | 2022 | 1232 | 0.110 |
Why?
|
Decision Support Systems, Clinical | 1 | 2022 | 1162 | 0.110 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4929 | 0.100 |
Why?
|
HIV-1 | 2 | 2020 | 6934 | 0.100 |
Why?
|
Stroke | 1 | 2014 | 9963 | 0.100 |
Why?
|
Fractures, Bone | 1 | 2023 | 1945 | 0.100 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2015 | 654 | 0.100 |
Why?
|
Prostatic Neoplasms | 1 | 2014 | 11039 | 0.100 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2012 | 323 | 0.100 |
Why?
|
Pharyngeal Diseases | 1 | 2012 | 132 | 0.100 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 712 | 0.100 |
Why?
|
Algorithms | 3 | 2023 | 13853 | 0.100 |
Why?
|
Directive Counseling | 1 | 2012 | 166 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2018 | 733 | 0.100 |
Why?
|
Renal Insufficiency | 1 | 2016 | 802 | 0.090 |
Why?
|
Data Collection | 1 | 2020 | 3339 | 0.090 |
Why?
|
Medicare | 2 | 2019 | 6532 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6483 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2016 | 15108 | 0.090 |
Why?
|
Tuberculosis | 1 | 2022 | 1904 | 0.090 |
Why?
|
Case-Control Studies | 2 | 2018 | 21719 | 0.090 |
Why?
|
Medicaid | 2 | 2023 | 2716 | 0.090 |
Why?
|
Heterosexuality | 1 | 2011 | 271 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 2167 | 0.080 |
Why?
|
Transsexualism | 1 | 2012 | 177 | 0.080 |
Why?
|
Alcoholism | 1 | 2019 | 1904 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2011 | 2970 | 0.080 |
Why?
|
Referral and Consultation | 2 | 2019 | 3527 | 0.080 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2000 | 3617 | 0.080 |
Why?
|
Boston | 2 | 2019 | 9305 | 0.080 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 552 | 0.080 |
Why?
|
Substance Abuse, Intravenous | 1 | 2013 | 522 | 0.080 |
Why?
|
Family Planning Services | 1 | 2011 | 258 | 0.080 |
Why?
|
Cause of Death | 1 | 2018 | 3571 | 0.080 |
Why?
|
Domestic Violence | 1 | 2009 | 176 | 0.080 |
Why?
|
Substance-Related Disorders | 2 | 2017 | 4250 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39004 | 0.070 |
Why?
|
Community Health Centers | 2 | 2022 | 428 | 0.070 |
Why?
|
Financing, Government | 1 | 2011 | 468 | 0.070 |
Why?
|
HIV Seropositivity | 2 | 2010 | 970 | 0.070 |
Why?
|
Survival Analysis | 2 | 2023 | 10248 | 0.070 |
Why?
|
Family Relations | 1 | 2009 | 321 | 0.070 |
Why?
|
Galactosyltransferases | 2 | 2000 | 263 | 0.070 |
Why?
|
Case Management | 1 | 2009 | 286 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2018 | 1794 | 0.070 |
Why?
|
Pilot Projects | 1 | 2019 | 8297 | 0.070 |
Why?
|
Comorbidity | 1 | 2020 | 10372 | 0.070 |
Why?
|
Logistic Models | 2 | 2018 | 13403 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12344 | 0.060 |
Why?
|
Chronic Disease | 1 | 2020 | 9144 | 0.060 |
Why?
|
Confidentiality | 1 | 2009 | 609 | 0.060 |
Why?
|
Time Factors | 3 | 2019 | 40054 | 0.060 |
Why?
|
Climate Change | 1 | 2010 | 410 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6534 | 0.060 |
Why?
|
Vaccination | 1 | 2016 | 3256 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 24913 | 0.060 |
Why?
|
Massachusetts | 3 | 2022 | 8662 | 0.060 |
Why?
|
Community Health Services | 1 | 2009 | 650 | 0.060 |
Why?
|
Ganglioside Galactosyltransferase | 2 | 2000 | 3 | 0.060 |
Why?
|
Program Evaluation | 1 | 2011 | 2485 | 0.050 |
Why?
|
Population Surveillance | 1 | 2013 | 2616 | 0.050 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2023 | 102 | 0.050 |
Why?
|
Health Surveys | 2 | 2009 | 4030 | 0.050 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5304 | 0.050 |
Why?
|
Alabama | 1 | 2022 | 98 | 0.050 |
Why?
|
Probability | 2 | 2023 | 2502 | 0.050 |
Why?
|
Basic Reproduction Number | 1 | 2021 | 31 | 0.050 |
Why?
|
Prescriptions | 1 | 2024 | 387 | 0.050 |
Why?
|
Ontario | 1 | 2022 | 381 | 0.050 |
Why?
|
Risk Assessment | 3 | 2021 | 23320 | 0.050 |
Why?
|
Self Report | 1 | 2012 | 3548 | 0.050 |
Why?
|
Galactolipids | 1 | 2000 | 4 | 0.050 |
Why?
|
Age Distribution | 2 | 2021 | 2900 | 0.050 |
Why?
|
Mice, Neurologic Mutants | 1 | 2000 | 126 | 0.050 |
Why?
|
Cultural Competency | 1 | 2023 | 288 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2018 | 5724 | 0.040 |
Why?
|
Qualitative Research | 2 | 2019 | 2680 | 0.040 |
Why?
|
Myelin Proteins | 1 | 2000 | 215 | 0.040 |
Why?
|
Depression | 1 | 2018 | 7733 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2019 | 57683 | 0.040 |
Why?
|
Education, Medical, Continuing | 1 | 2023 | 839 | 0.040 |
Why?
|
North America | 1 | 2021 | 1249 | 0.040 |
Why?
|
Policy | 1 | 2021 | 504 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 9941 | 0.040 |
Why?
|
Pregnancy | 2 | 2021 | 29087 | 0.040 |
Why?
|
Self Efficacy | 1 | 2020 | 610 | 0.040 |
Why?
|
Cell Count | 1 | 2000 | 1831 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1215 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2533 | 0.030 |
Why?
|
Aging | 1 | 2014 | 8626 | 0.030 |
Why?
|
Postpartum Period | 1 | 2021 | 1078 | 0.030 |
Why?
|
Schools | 1 | 2023 | 1425 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2022 | 1048 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2021 | 1320 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2303 | 0.030 |
Why?
|
Perception | 1 | 2020 | 1188 | 0.030 |
Why?
|
Selection, Genetic | 1 | 2019 | 914 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 15056 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20774 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2015 | 11690 | 0.030 |
Why?
|
Bacterial Typing Techniques | 1 | 2013 | 256 | 0.030 |
Why?
|
Genes | 1 | 1996 | 1892 | 0.030 |
Why?
|
Axons | 1 | 2000 | 1681 | 0.030 |
Why?
|
Spinal Cord | 1 | 2000 | 1807 | 0.030 |
Why?
|
Phylogeny | 1 | 2019 | 2797 | 0.020 |
Why?
|
RNA | 1 | 2000 | 2747 | 0.020 |
Why?
|
Markov Chains | 1 | 2013 | 969 | 0.020 |
Why?
|
Mental Disorders | 1 | 2009 | 6587 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2013 | 5385 | 0.020 |
Why?
|
Computer Simulation | 1 | 2023 | 6191 | 0.020 |
Why?
|
Odds Ratio | 2 | 2011 | 9846 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3510 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1653 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2013 | 1679 | 0.020 |
Why?
|
Child, Preschool | 1 | 2009 | 40955 | 0.020 |
Why?
|
Cognition | 1 | 2024 | 6722 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2013 | 1032 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 1184 | 0.020 |
Why?
|
Public Policy | 1 | 2010 | 572 | 0.020 |
Why?
|
Decision Making | 1 | 2019 | 3869 | 0.020 |
Why?
|
Research Personnel | 1 | 2010 | 573 | 0.020 |
Why?
|
Politics | 1 | 2010 | 790 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2000 | 11470 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 13921 | 0.010 |
Why?
|
Research | 1 | 2010 | 1999 | 0.010 |
Why?
|
Mice | 2 | 2000 | 81045 | 0.010 |
Why?
|
Women's Health | 1 | 2011 | 2034 | 0.010 |
Why?
|
Child | 1 | 2009 | 77478 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2009 | 1737 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2009 | 6365 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12017 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1996 | 441 | 0.010 |
Why?
|
Prospective Studies | 1 | 2020 | 53187 | 0.010 |
Why?
|
Glucuronosyltransferase | 1 | 1996 | 128 | 0.010 |
Why?
|
Public Health | 1 | 2009 | 2594 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29717 | 0.010 |
Why?
|
Databases, Factual | 1 | 2009 | 7716 | 0.010 |
Why?
|
Species Specificity | 1 | 1996 | 2479 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1996 | 2837 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1996 | 2257 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15530 | 0.010 |
Why?
|
Animals | 2 | 2000 | 168561 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1996 | 4322 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1996 | 2638 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1996 | 4742 | 0.000 |
Why?
|
Base Sequence | 1 | 1996 | 12797 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 13814 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1996 | 18112 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1996 | 7721 | 0.000 |
Why?
|
Rats | 1 | 1996 | 24265 | 0.000 |
Why?
|